Steve Oesterle is a venture partner with Cathay Health and the CBC Group. Most recently, Steve has worked on VC and PE investments as venture partner or advisor with NEA, EQT and Temasek. Previously, Steve served as Medtronic’s Senior Vice President for Medicine and Technology and was a member of the Medtronic Executive Committee for 14 years. By forging relationships with global technology partners and technical universities, he oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of the Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic Steve served on more than 20 boards as a director or observer and built a strong and enduring profile for Medtronic in the global venture capital and private equity communities.
Steve currently serves on the public boards of healthcare MNC Baxter (NYSE: BAX), Boston biotech/cell therapy company Sigilon Therapeutics (NASDAQ. SGTX), Shanghai cardiovascular device company Peijia Medical (HKG: 9996) and Paragon 28, a Foot and Ankle orthopedic company (NYSE: FNA). He also serves on PE backed companies – CeramTec (CPPIB and BC Partners) global leader in medical and industrial ceramic products, and SHL Medical AG (EQT minority), a market leader in auto injectors for biologics and VC backed companies Alcyone Therapeutics - targeted gene therapy for CNS. He is also on the advisory board of Alphabet’s healthcare company, Verily.
Steve graduated summa cum laude from Harvard and received his medical degree from Yale; he completed his internship and residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the faculty at Stanford and Harvard Medical Schools and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford.